Press Releases

YEAR
Toggle Summary Nabriva Therapeutics to Present Lefamulin Data at ASM Microbe
Potential of Lefamulin to Treat Patients with CABP Against Backdrop of Increasing Bacterial Resistance Presented on Eight Posters DUBLIN, Ireland , May 31, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and
View HTML
Toggle Summary Nabriva Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , May 29, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class
View HTML
Toggle Summary Nabriva Therapeutics Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia
- Lefamulin met all FDA and EMA primary endpoints  and was shown to be generally well tolerated - - Company plans to file a New Drug Application with the U.S. Food and Drug Administration  in the fourth quarter of 2018 - - Conference call and webcast today at 8:30 a.m.
View HTML
Toggle Summary Nabriva Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
- Topline data from second pivotal Phase 3 trial of lefamulin for CABP (LEAP 2) expected in Spring 2018 - - $90 million cash and investments as of March 31, 2018 expected to fund operations into the first quarter of 2020 - DUBLIN, Ireland , May 08, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc
View HTML
Toggle Summary Nabriva Therapeutics to Participate in Two Investor Conferences in May
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , April 25, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin
View HTML
Toggle Summary Nabriva Therapeutics to Present Data at ECCMID Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia
Six abstracts support lefamulin as a potential first-in-class pleuromutilin antibiotic targeting CABP pathogens, including drug resistant phenotypes DUBLIN, Ireland , April 13, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the
View HTML
Toggle Summary Nabriva Therapeutics and Roivant Sciences Enter into License Agreement to Develop and Commercialize Lefamulin in Greater China
DUBLIN, Ireland and HONG KONG , March 27, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of
View HTML
Toggle Summary Nabriva Therapeutics Appoints Jennifer Schranz, M.D., as Chief Medical Officer
Dr. Schranz to lead the company’s clinical development and medical affairs organization with a focus on advancing lefamulin, its lead investigational program DUBLIN, Ireland and KING OF PRUSSIA, Pa. , March 21, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage
View HTML
Toggle Summary Nabriva Therapeutics Reports 2017 Financial Results and Recent Corporate Highlights
- Positive topline results from pivotal LEAP 1 trial announced in September 2017 , with read-out from second Phase 3 trial, LEAP 2, expected in the spring of 2018 - - $86.9 million cash and investments as of December 31, 2017 - DUBLIN, Ireland , March 16, 2018 (GLOBE NEWSWIRE) -- Nabriva
View HTML
Toggle Summary Nabriva Therapeutics to Present at the Needham and Company 17th Annual Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , March 14, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin
View HTML

For Media Inquiries

PR@nabriva.com


For Investor Relations

David Garrett
Vice President, Corporate Controller and Head of Investor Relations
Nabriva Therapeutics plc

E-mail: david.garrett@nabriva.com